Skip to main content

Medications for Non-Radiographic Axial Spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA) is a chronic inflammatory condition characterized by inflammation of the spine and sacroiliac joints, which connect the lower spine and pelvis. Non-radiographic means that no damage is visible on an x-ray.

The exact cause of nr-AxSpA is not clear, though genetic factors may be involved. People with a gene called HLA-B27 are thought to have an increased risk.

Symptoms of nr-axSpA include inflammatory back pain, prolonged and severe stiffness, fatigue, and sleep disturbances resulting in reduced physical function, decreased quality of life, impaired work and home productivity and social participation.

Treatments for nr-axSpA include nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, disease-modifying antirheumatic drugs (DMARDs), corticosteroids, and biologics.

Drugs used to treat Non-Radiographic Axial Spondyloarthritis

The following list of medications are in some way related to or used in the treatment of this condition.

Filter
Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
Cimzia 3.0 3 reviews for Cimzia to treat Non-Radiographic Axial Spondyloarthritis
Rx B N

Generic name: certolizumab systemic

Drug class: TNF alfa inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

Cosentyx 4.0 4 reviews for Cosentyx to treat Non-Radiographic Axial Spondyloarthritis
Rx B N

Generic name: secukinumab systemic

Drug class: interleukin inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

Taltz 5.7 3 reviews for Taltz to treat Non-Radiographic Axial Spondyloarthritis
Rx N

Generic name: ixekizumab systemic

Drug class: interleukin inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

secukinumab 4.0 4 reviews for secukinumab to treat Non-Radiographic Axial Spondyloarthritis
Rx B N

Generic name: secukinumab systemic

Brand name:  Cosentyx

Drug class: interleukin inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph

ixekizumab 4.5 4 reviews for ixekizumab to treat Non-Radiographic Axial Spondyloarthritis
Rx N

Generic name: ixekizumab systemic

Brand name:  Taltz

Drug class: interleukin inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph

certolizumab 3.0 3 reviews for certolizumab to treat Non-Radiographic Axial Spondyloarthritis
Rx B N

Generic name: certolizumab systemic

Brand name:  Cimzia

Drug class: TNF alfa inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph

Rinvoq Rate Add review
Rx N

Generic name: upadacitinib systemic

Drug class: antirheumatics

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

upadacitinib Rate Add review
Rx N

Generic name: upadacitinib systemic

Brand name:  Rinvoq

Drug class: antirheumatics

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph

Frequently asked questions

View more FAQ

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Prescription only.
OTC Over-the-counter.
Rx/OTC Prescription or Over-the-counter.
Off-label This medication may not be approved by the FDA for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Expanded Access Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.